MCP-1-based GAGbody™

About Antagonis Biotherapeutics

Antagonis Biotherapeutics is an early-stage Austrian biotech pioneering a novel approach to targeting glycosaminoglycans (GAGs)—a challenging class of polysaccharides involved in cancer metastasis and other diseases. The company's core asset is its GAGbody™ platform, which engineers natural GAG-binding proteins into therapeutic proteins with extended half-life, aiming to block pro-metastatic chemokine signaling. With a lead candidate showing efficacy in a murine metastasis model, Antagonis is positioned as both a platform company and a therapeutics developer, actively seeking partnerships to advance its pipeline. The company benefits from a strong academic foundation at the University of Graz and an experienced leadership team with backgrounds in drug discovery and biologics development.

Therapeutic Areas